Objective We investigated whether elevated levels of circulating platelet-leukocyte aggregates (PLA) can be used to identify acute myocardial infarction patients with no-reflow.
Methods 120 patients with acute myocardial infarction (AMI) (72 male/48 female, mean age: 65.6 ± 8.6 years), undergoing successfully percutaneous coronary intervention (PCI), were studied and their PLA was measured by flow cytometry. PLA were identified as platelet-neutrophil aggregates (PNA) and platelet-monocyte aggregates (PMA). No-reflow was defined as a coronary TIMI flow grade ≤ 2 after vessel reopening or TIMI flow 3 with a final MBG ≤ 2. Blood samples were obtained before PCI. Logistic regression models were developed with adjustment for confounders.
Result Compared with normal reflow group (n = 95), no-reflow group (n = 25) had significantly higher counts of circulating PNA (p < 0.001) and PMA (p < 0.001). In univariable logistic regression models, diabetes mellitus, lesion length, reference luminal diameter, thrombus score ≥ 4, circulating levels of PNA and PMA were all found to be positively associated with the risk of no-reflow (p < 0.05). After adjusting for these factors, circulating levels of PNA (OR 4.156, 95% CI : 2.435–8.168; p = 0.006) and PMA (OR 5.132, 95% CI: 2: 135–7.218; p = 0.007) were found to be independent risk factors of no-reflow together with diabetes mellitus (OR 10.134, 95% CI: 2.234–35.342; p = 0.029).
Conclusion Circulating PLA is a sensitive marker of no-reflow in AMI patients.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.